Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)

Next Previous
Trial Profile

A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emrusolmin (Primary)
  • Indications Multiple system atrophy
  • Focus Therapeutic Use
  • Acronyms TOPAS-MSA
  • Sponsors Teva Branded Pharmaceutical Products R&D

Most Recent Events

  • 19 Feb 2026 Planned number of patients changed from 200 to 350.
  • 19 Feb 2026 Company plan to open locations in the following countries: US, Israel, Italy, Spain, Germany, France, Japan, and Serbia.
  • 19 Feb 2026 Planned End Date changed from 17 Jun 2027 to 15 Sep 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top